MedTrace Logo

A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

NCT04777175 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2024-09-19

No results posted yet for this study

Summary

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

immunity therapy

The patient receives immunotherapy

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    collaborator OTHER

  • Yongchang Zhang

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-01-01
Completion
2025-01-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04777175 on ClinicalTrials.gov